ESC Premium Access

The role of SGLT2 inhibitors in CV risk reduction in patients with type 2 diabetes

Topic: Diabetes and the Heart
Sponsored by The Boehringer Ingelheim, Eli Lilly and Company Alliance

Congress Presentation

About the speaker

Professor Sanjay Kaul

Cedars-Sinai Medical Centre, Los Angeles (United States of America)
1 presentation
0 follower

4 more presentations in this session

Welcome and introduction

Speaker: Professor T. Luscher (London, GB)

Thumbnail

Taking the initiative: the cardiologist´s perspective

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

The SGLT2 inhibitor era: what more can we expect?

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Audience questions and answers, summary and close

Speaker: Professor T. Luscher (London, GB)

Thumbnail

Access the full session

SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes

Speakers: Professor S. Kaul, Professor T. Luscher, Professor N. Marx, Professor S. Anker, Professor T. Luscher
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk